Argenica Therapeutics Ltd (AGN) Price & Analysis

Q: What was Argenica Therapeutics Ltd’s price range in the past 12 months?

Argenica Therapeutics Ltd lowest share price was AU$0.19 and its highest was AU$0.89 in the past 12 months.

Q: When is Argenica Therapeutics Ltd’s upcoming earnings report date?

Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 03, 2026 which is in 80 days.

Q: How were Argenica Therapeutics Ltd’s earnings last quarter?

Argenica Therapeutics Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.047 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.047.

Q: Is Argenica Therapeutics Ltd overvalued?

According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Argenica Therapeutics Ltd pay dividends?

Argenica Therapeutics Ltd does not currently pay dividends.

Q: What is Argenica Therapeutics Ltd’s EPS estimate?

Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Argenica Therapeutics Ltd have?

Argenica Therapeutics Ltd has 128,456,710 shares outstanding.

Q: What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?

Argenica Therapeutics Ltd reported an EPS of -AU$0.047 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.478%.

Q: Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?

Currently, no hedge funds are holding shares in AU:AGN

Compare

12 Followers

AGN Stock Chart & Stats

AU$0.29

<AU$0.01(0.81%)

At close: Jan 09 4:00 PM EST

AU$0.29

<AU$0.01(0.81%)

Day’s Range― - ―

52-Week RangeAU$0.19 - AU$0.89

Previous CloseN/A

Volume9.34K

Average Volume (3M)511.75K

Market Cap

N/A

Enterprise ValueAU$87.06M

Total Cash (Recent Filing)AU$10.56M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding128,456,710

10 Day Avg. Volume288,263

30 Day Avg. Volume511,745

Financial Highlights & Ratios

PEG Ratio-2.24

Price to Book (P/B)13.39

Price to Sales (P/S)30.16

P/FCF Ratio-16.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.63

Price Target Upside117.24% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Argenica Therapeutics Ltd News

Argenica’s ARG-007 Shows Promising Results in Severe Stroke Patients

Argenica Therapeutics Ltd ( ($AU:AGN) ) has provided an update. Argenica Therapeutics has announced significant findings from an...

2d ago

AGN

Argenica’s ARG-007 Shows Promising Results in Preclinical Stroke Study

The latest update is out from Argenica Therapeutics Ltd ( ($AU:AGN) ). Argenica Therapeutics has announced successful independent...

18d ago

AGN

Argenica Therapeutics AGM Resolutions Passed Successfully

Argenica Therapeutics Ltd ( ($AU:AGN) ) just unveiled an update. Argenica Therapeutics Limited announced the successful passage of...

1M ago

AGN

Argenica Therapeutics Advances ARG-007 Amidst Clinical and Market Challenges

An announcement from Argenica Therapeutics Ltd ( ($AU:AGN) ) is now available. Argenica Therapeutics has completed its first...

1M ago

AGN

Argenica Therapeutics Announces Retirement of Key Board Member

Argenica Therapeutics Ltd ( ($AU:AGN) ) just unveiled an update. Argenica Therapeutics announced the retirement of Mr. Terry...

1M ago

AGN

Argenica Therapeutics Advances Stroke Treatment with Promising Trial Results

Argenica Therapeutics Ltd ( ($AU:AGN) ) has provided an announcement. Argenica Therapeutics has announced the successful completion of...

1M ago

AGN

Argenica Therapeutics Issues New Equity Securities as Part of Employee Incentive Scheme

Argenica Therapeutics Ltd ( ($AU:AGN) ) has issued an announcement. Argenica Therapeutics Ltd announced the issuance of 200,000...

2M ago

AGN

Argenica Therapeutics Reports Positive Phase 2 Trial Results for Stroke Treatment

Argenica Therapeutics Ltd ( ($AU:AGN) ) has shared an announcement. Argenica Therapeutics Limited announced promising results from its...

2M ago

AGN

Argenica Therapeutics Announces Details for Upcoming Annual General Meeting

The latest announcement is out from Argenica Therapeutics Ltd ( ($AU:AGN) ). Argenica Therapeutics Limited has announced the...

2M ago

AGN

Argenica Therapeutics Unveils Strategic Presentation at ASX Conference

The latest update is out from Argenica Therapeutics Ltd ( ($AU:AGN) ). Argenica Therapeutics Ltd has released a...

3M ago

AGN

AGN FAQ

What was Argenica Therapeutics Ltd’s price range in the past 12 months?

Argenica Therapeutics Ltd lowest share price was AU$0.19 and its highest was AU$0.89 in the past 12 months.

What is Argenica Therapeutics Ltd’s market cap?

Currently, no data Available

When is Argenica Therapeutics Ltd’s upcoming earnings report date?

Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 03, 2026 which is in 80 days.

How were Argenica Therapeutics Ltd’s earnings last quarter?

Argenica Therapeutics Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.047 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.047.

Is Argenica Therapeutics Ltd overvalued?

According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Argenica Therapeutics Ltd pay dividends?

Argenica Therapeutics Ltd does not currently pay dividends.

What is Argenica Therapeutics Ltd’s EPS estimate?

Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Argenica Therapeutics Ltd have?

Argenica Therapeutics Ltd has 128,456,710 shares outstanding.

What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?

Argenica Therapeutics Ltd reported an EPS of -AU$0.047 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.478%.

Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?

Currently, no hedge funds are holding shares in AU:AGN

Argenica Therapeutics Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-67.68%

Trailing 12-Months

Asset Growth

-32.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Argenica Therapeutics Ltd

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.

Argenica Therapeutics Ltd (AGN) Earnings & Revenues

Historic Earnings Reports

AGN Stock 12 Month Forecast

Average Price Target

AU$0.63

▲(117.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,0.2884615384615385,0.3169230769230769,0.3453846153846154,0.37384615384615383,0.4023076923076923,0.4307692307692308,0.4592307692307692,0.4876923076923077,0.5161538461538462,0.5446153846153846,0.573076923076923,0.6015384615384616,{"y":0.63,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,0.2884615384615385,0.3169230769230769,0.3453846153846154,0.37384615384615383,0.4023076923076923,0.4307692307692308,0.4592307692307692,0.4876923076923077,0.5161538461538462,0.5446153846153846,0.573076923076923,0.6015384615384616,{"y":0.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,0.2884615384615385,0.3169230769230769,0.3453846153846154,0.37384615384615383,0.4023076923076923,0.4307692307692308,0.4592307692307692,0.4876923076923077,0.5161538461538462,0.5446153846153846,0.573076923076923,0.6015384615384616,{"y":0.63,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.63,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >